Three-dimensional model of cytochrome P450 human aromatase

被引:17
作者
Loge, C
Le Borgne, M
Marchand, P
Robert, JM
Le Baut, G
Palzer, M
Hartmann, RW
机构
[1] UFR Sci Pharmaceut, Dept Pharmacochim Biomol & Cibles Therapeut, UPRES EA 1155, F-44035 Nantes, France
[2] Univ Saarland, D-660041 Saarbrucken, Germany
关键词
breast cancer; CYP19; aromatase; homology modeling; active site; inhibitors; S-fadrozole;
D O I
10.1080/14756360500220574
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A three-dimensional ( 3-D) structure of human aromatase ( CYP19) was modeled on the basis of the crystal structure of rabbit CYP2C5, the first solved X-ray structure of an eukaryotic cytochrome P450 and was evaluated by docking S-fadrozole and the steroidal competitive inhibitor ( 19R)-10-thiiranylestr-4-ene-3,17-dione, into the enzyme active site. According to a previous pharmacophoric hypothesis described in the literature, the cyano group of S-fadrozole partially mimics the steroid backbone C( 17) carbonyl group of ( 19R)-10-thiiranylestr-4-ene-3,17-dione, and was oriented in a favorable position for H-bonding with the newly identified positively charged residues Lys119 and Arg435. In addition, this model is consistent with the recent combined mutagenesis/modeling studies already published concerning the roles of Asp309 and His480 in the aromatization of the steroid A ring.
引用
收藏
页码:581 / 585
页数:5
相关论文
共 24 条
  • [1] Ahmed S, 1998, Drug Des Discov, V15, P239
  • [2] Study of substrate specificity of human aromatase by site directed mutagenesis
    Auvray, P
    Nativelle, C
    Bureau, R
    Dallemagne, P
    Séralini, GE
    Sourdaine, P
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 2002, 269 (05): : 1393 - 1405
  • [3] Linking CoMFA and protein homology models of enzyme-inhibitor interactions: an application to non-steroidal aromatase inhibitors
    Cavalli, A
    Greco, G
    Novellino, E
    Recanatini, M
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2000, 8 (12) : 2771 - 2780
  • [4] Structure-function studies of aromatase and its inhibitors: a progress report
    Chen, SA
    Zhang, FM
    Sherman, MA
    Kijima, I
    Cho, M
    Yuan, YC
    Toma, Y
    Osawa, Y
    Zhou, DJ
    Eng, ET
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2003, 86 (3-5) : 231 - 237
  • [5] VALIDATION OF THE GENERAL-PURPOSE TRIPOS 5.2 FORCE-FIELD
    CLARK, M
    CRAMER, RD
    VANOPDENBOSCH, N
    [J]. JOURNAL OF COMPUTATIONAL CHEMISTRY, 1989, 10 (08) : 982 - 1012
  • [6] AROMATASE INHIBITORS - SYNTHESIS, BIOLOGICAL-ACTIVITY, AND BINDING MODE OF AZOLE-TYPE COMPOUNDS
    FURET, P
    BATZL, C
    BHATNAGAR, A
    FRANCOTTE, E
    RIHS, G
    LANG, M
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (10) : 1393 - 1400
  • [7] A 3-DIMENSIONAL MODEL OF AROMATASE CYTOCHROME-P450
    GRAHAMLORENCE, S
    AMARNEH, B
    WHITE, RE
    PETERSON, JA
    SIMPSON, ER
    [J]. PROTEIN SCIENCE, 1995, 4 (06) : 1065 - 1080
  • [8] Structural alignments of P450s and extrapolations to the unknown
    GrahamLorence, SE
    Peterson, JA
    [J]. CYTOCHROME P450, PT B, 1996, 272 : 315 - 326
  • [9] Aromatase inhibitors for breast cancer: Lessons from the laboratory
    Johnston, SRD
    Dowsett, M
    [J]. NATURE REVIEWS CANCER, 2003, 3 (11) : 821 - 831
  • [10] MOLECULAR RECOGNITION OF RECEPTOR-SITES USING A GENETIC ALGORITHM WITH A DESCRIPTION OF DESOLVATION
    JONES, G
    WILLETT, P
    GLEN, RC
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1995, 245 (01) : 43 - 53